Neurobiological Technologies, Inc.
NTII · OTC
6/30/2010 | 6/30/2009 | 6/30/2008 | 6/30/2007 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.05 | 0.02 | 0.07 |
| FCF Yield | 0.00% | -90.40% | -75.03% | -24.46% |
| EV / EBITDA | 0.00 | 3.06 | 0.02 | -3.16 |
| Quality | ||||
| ROIC | 0.00% | 14.83% | -48.90% | 472.61% |
| Gross Margin | 0.00% | 99.50% | 98.61% | 98.70% |
| Cash Conversion Ratio | -5.26 | 1.27 | 0.93 | -0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.24% | 6.15% | 78.65% | 64.21% |
| Free Cash Flow Growth | 0.00% | 20.65% | -56.64% | -252.80% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -2.53 | 1.69 | 0.36 |
| Interest Coverage | 0.00 | 0.00 | -6.74 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -55.52 | -1,032.11 | -2,562.30 |